Efficacy of Adjuvant Immune-cell Therapy Combined With Systemic Therapy for Solid Tumors

Background/Aim: The efficacy of adjuvant systemic therapy after surgical resection remains unsatisfactory; therefore, a new treatment strategy is required. We aimed to examine the efficacy of adjuvant immune-cell therapy using activated T lymphocytes with or without dendritic cell vaccination in com...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2022-08, Vol.42 (8), p.4179-4187
Main Authors: Takimoto, Rishu, Kamigaki, Takashi, Okada, Sachiko, Ibe, Hiroshi, Oguma, Eri, Goto, Shigenori
Format: Article
Language:English
Subjects:
Breast cancer
Cell therapy
Dendritic cells
Health services
Lymphocytes
Lymphocytes T
Multivariate analysis
Patients
Solid tumors
Survival
Therapy
Tumors
Vaccination
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aim: The efficacy of adjuvant systemic therapy after surgical resection remains unsatisfactory; therefore, a new treatment strategy is required. We aimed to examine the efficacy of adjuvant immune-cell therapy using activated T lymphocytes with or without dendritic cell vaccination in combination with standard adjuvant systemic therapies in terms of the survival of patients with solid tumors, such as lung, gastric, pancreatic, colorectal, and breast cancers. Patients and Methods: A total of 141 patients with solid tumors were enrolled in this study. The correlation of overall survival and disease-free survival with various clinical factors such as age, sex, performance status score, clinical stage, treatment strategies, and vital status was investigated by univariate and multivariate analyses. Results: Multivariate analysis revealed that a performance status score of 0 was a favorable prognostic factor in the full analysis set of solid tumors (HR=0.209, 95%CI=0.065-0.676, p=0.0089) and might be the indication for immune-cell therapy in the adjuvant setting. Conclusion: Adjuvant immune-cell therapy combined with other systemic therapies would potentially provide a survival benefit in patients with solid tumors.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.15918